Biodesix

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biodesix reports robust Q4 revenue growth and expands reimbursement coverage

Biodesix's strong revenue growth and progress in reimbursement coverage underscore its position in the lung diagnostic testing market.
Continued success with newer tests like Nodify XL2 and Nodify CDT presents opportunities for further expansion and increased payer acceptance.

Biodesix reports robust Q1 revenue growth amidst operational challenges

Biodesix's Q1 2023 performance reflects strong revenue growth driven by core lung diagnostics and test volume expansion.
While facing challenges such as increased operating expenses and delayed clinical trials, the company maintains a focus on growth.
Opportunities lie in leveraging their precision tests portfolio, revenue diversification, and strategic investments for future growth.

Biodesix reports robust Q2 earnings, eyes sustained growth trajectory

Biodesix's Q2 2023 performance reflects strong revenue growth and improved margins, driven by core lung diagnostic tests.
While facing challenges in revenue diversification and cost management, the company's focus on clinical utility and growth opportunities remains promising.
With upcoming conference presentations and investor support, Biodesix is poised to sustain growth and advance towards profitability.

Biodesix reports robust Q3 earnings and strategic growth initiatives

Biodesix delivered a strong Q3 performance with revenue growth, improved margins, and cost management.
The company faces challenges in study timelines and commercialization but has opportunities in market expansion and product development.
By focusing on sales force expansion, quality culture, and cost control, Biodesix is positioning itself for future success.
Investors should note the company's resilience, growth potential, and strategic focus on profitability and market expansion.

Biodesix reports robust 2023 performance, eyes sustained growth in 2024

Biodesix's strong 2023 performance in revenue growth and margin improvement sets the stage for sustained growth in 2024.
The company's focus on operational efficiency, market expansion, and test adoption positions it well for future success.
Challenges in sustaining growth momentum and managing costs are balanced by opportunities in market penetration and profitability.
Investments in sales expansion and ongoing clinical studies present avenues for continued growth and innovation in the coming year.

Biodesix reports robust Q1 performance, focuses on growth strategies

Biodesix's Q1 2024 performance reflects strong revenue growth and operational achievements, despite a net loss.
Strategic partnerships and financial initiatives position the company well for future growth and innovation.
Addressing profitability challenges and operational efficiency will be key for Biodesix's sustained success in the competitive healthcare market.

Biodesix reports robust Q2 growth, raises revenue guidance for 2024

Biodesix's Q2 2024 performance reflects strong revenue growth and operational improvements, despite some profitability challenges.
The company's focus on innovation in lung cancer care and positive workplace culture position it well for future success.
With increased revenue guidance, expanding market opportunities, and a commitment to impact healthcare, Biodesix shows promise for continued growth.

Biodesix reports robust Q3 performance amidst revenue growth challenges

Biodesix demonstrated strong financial performance in Q3 2024 with revenue growth, improved margins, and a focus on innovation.
While facing challenges in biopharma services revenue and operational disruptions, the company remains resilient and proactive.
Opportunities lie in revenue growth through lung volume increase, addressing payment issues, and expanding sales team effectiveness.
Overall, Biodesix's strategic focus on growth and efficiency positions it well for future success in the diagnostics market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at Cowen's 42nd Annual Healthcare Conference being held virtually March 7-9, 2022. Cowen's 42nd Annual Healthcare Conference Date: Tuesday, March 8, 2022 Time: 2:50 PM ET The presentation will be webcast live and available for replay under “News & Events” in the Investo

Biodesix to Present at Cowen's 42nd Annual Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021 before the open of trading on Monday, March 14. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Dial-in and call de

Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that its Chief Executive Officer was named in The Healthcare Technology Report's list of Top 25 Biotech CEOs of 2022. The annual list recognizes the most accomplished executives in the biotech industry. An extensive process was run to evaluate the hundreds of CEOs who were nominated this year. These CEOs lead exemplary organizations in t

Biodesix CEO Scott Hutton Named to The Healthcare Technology Report's List of Top 25 Biotech CEOs in 2022

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report fourth quarter and record full-year 2021 preliminary unaudited total revenue of $7.2 million and $54.5 million, respectively. The strength in the full-year 2021 total revenue of $54.5 million compared to $45.6 million in 2020 was a result of growth in the Company's core lung diagnostic testing and first

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held virtually February 15-17, 2022. BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Date: Wednesday, February 16, 2022 Time: 4:30 PM ET

Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

ST. LOUIS--(BUSINESS WIRE)-- #precisionmedicine--PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics.

PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today the national launch of its new GeneStrat NGS™ genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced- stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an ex

Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder,

Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

MEMPHIS, Tenn.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Spesana, the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the United States utilizing Spesana's digital platform solutions for comprehensive lung cancer management. Spesana is a cloud based Digita

Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) utilizing its novel predictive and prognostic blood-based host immune classifier (the VeriStrat test) to stratify Immune che

Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer

Biodesix, Inc. (BDSX) CEO Scott Hutton on Q3 2021 Results - Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2021 and provided a corporate update. “The third quarter was highlighted by the growth of our core lung diagnostics and biopharma service product offerings, which grew year-over-year 51% and 133% respectively, despite the headwinds from the COVID-19 Delta vari

Biodesix Announces Third Quarter 2021 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company will co-present with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), three posters at the 36th Annual Society for Immunotherapy of Cancer (SITC) Nov. 10 – 14, 2021 from research into diagnostic tests of treatment response of NSCLC patients to immune checkpoint inhibitor therapy. “Biodesix is committ

Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021. Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum Date: Thursday, November 18, 2021

Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biodesix, Inc. (BDSX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 9:00 a.m. Eastern Time on the same day. Dial-in and call details

Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference. Presentations will include newly emerging data from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test - ORACLE [NCT03766958]), demonstrating that incorporation of this blood-based test in t

Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC). The Role of Serum Proteomic Signature in Predicting Survival by PD-L1 Status in Patients with Non-Small Cell Lung Cancer R

Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat the Morgan Stanley Virtual 19th Annual Global Healthcare Conference being held virtually September 9-10 and September 13-15, 2021. Morgan Stanley Virtual 19th Annual Global Healthcare Conference Date: Thursday, September 9, 2021 Time: 4:15 PM ET The fires

Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in DeSoto, Kansas, based on results of two independent inspections conducted by CAP and BSI inspectors. The CAP advised

Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists

Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2021 Results - Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2021 and provided a corporate update. “It was a productive quarter with 180% year over year growth in total revenue. Our first four blood-based tests which make up our core lung diagnostic testing, grew 109% year over year and 20% over the prior quarter,” said Sco

Biodesix Announces Second Quarter 2021 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021. Canaccord Genuity 41st Annual Growth Conference Date: Thursday, August 12, 2021 Time: 12:30 PM ET The presentation will be webcast live and available for replay under “News &

Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the second quarter ended June 30, 2021 after the close of trading on Tuesday, August 10. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Dial-in and call details are a

Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021

Seer

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present the newest trends in proteomics for biomarker discovery and translational research. The webinar entitled “A New Era in Precision Medicine - Uncovering the Depth & Breadth of the Plasma Proteome with Novel Proteomi

News for Biodesix Stock (BDSX)